A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab
Xeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations.
Authors
- Lunfei Liu (ORCID: https://orcid.org/0000-0003-3200-4279)
- Jian Pan (ORCID: https://orcid.org/0000-0002-2673-1333)
- Binbin Hu (ORCID: https://orcid.org/0000-0002-0443-1401)
- Jun Ma (ORCID: https://orcid.org/0000-0002-1137-9349)
Institutions
- Zhejiang International Studies University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1651568
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Zhejiang University